NeuroSense Therapeutics, a company specializing in the development of treatments for severe neurodegenerative diseases, announced that its ALS treatment trials have achieved primary safety and tolerability endpoints, as well as secondary clinical efficacy endpoints.
Following this announcement, the stock experienced significant fluctuations. In postmarket trading on Monday, shares surged by as much as 48% above the previous closing price of $1.49. However, in premarket trading on Tuesday morning, the stock took a dip, falling by 28% to $1.07 at 8:38 a.m. ET.
NeuroSense’s phase 2b clinical trial for PrimeC, their treatment for amyotrophic lateral sclerosis (ALS), demonstrated promising results. During a six-month period, patients in Italy, Israel, and Canada who received PrimeC experienced a notable slowdown in disease progression, with preserved daily function.
The clinical efficacy results highlighted a significant difference in favor of PrimeC. The ALS functional rating scale revised showed a 29% improvement, while slow vital capacity, a measure of respiratory function, showed a 13% improvement. These results were based on data from 68 out of 69 patients, with one participant being misdiagnosed.
NeuroSense’s commitment to developing effective treatments for neurodegenerative diseases shows promise with these positive trial results.
